» Articles » PMID: 35166966

Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2022 Feb 15
PMID 35166966
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Nonalcoholic fatty liver disease is common and under-diagnosed. This study evaluated the accuracy of several previously reported indices, including hepatic steatosis index, alanine aminotransferase (ALT) method, Framingham steatosis index, and Dallas steatosis index, to diagnose hepatic steatosis in a real-world cohort.

Methods: This study included 701 randomly selected adult patients seen in our integrated healthcare system between 2015 and 2020 with appropriate abdominal imaging and routine outpatient laboratory studies. Information on demographics, comorbidities and existing liver disease, anthropometrics, laboratory studies, and abdominal imaging was collected. The sensitivity, specificity, and C-statistic of each method in detecting hepatic steatosis based on abdominal imaging were determined.

Results: 202/701 patients (28.8%) had hepatic steatosis on abdominal imaging. These patients were more likely to have metabolic syndrome components and higher body mass index. All indices performed similarly with moderate accuracy in detecting hepatic steatosis based on the C-statistic (95% confidence interval): Hepatic steatosis index 0.76 (0.72-0.79), Framingham steatosis index 0.78 (0.74-0.82), and Dallas steatosis index 0.80 (0.76-0.83). ALT method had sensitivity 44.7% (36.9-52.7%) and specificity 88.6% (85.0-91.7%). Several sensitivity analyses were performed, which did not significantly alter the performance of any index.

Conclusion: The findings support both the clinical utility of these indices in diagnosing hepatic steatosis in the absence of imaging in real-world settings and the research utility of these indices in generating reliable electronic medical record-based nonalcoholic fatty liver disease cohorts.

Citing Articles

The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.

Xia M, Lu Y, Yin F, Cao Z, Yao P, Li H J Gastroenterol. 2025; .

PMID: 39994040 DOI: 10.1007/s00535-025-02220-4.


Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application.

Chen V, Brady G Hepatol Commun. 2025; 9(1.

PMID: 39774697 PMC: 11717516. DOI: 10.1097/HC9.0000000000000618.


Assessing the clinical utility of major indices for nonalcoholic fatty liver disease in East Asian populations.

Hang Y, Lee C, Roman Y Biomark Med. 2023; 17(8):445-454.

PMID: 37449859 PMC: 10463214. DOI: 10.2217/bmm-2023-0172.


Effects of social determinants of health on mortality and incident liver-related events and cardiovascular disease in steatotic liver disease.

Chen V, Song M, Suresh D, Wadhwani S, Perumalswami P Aliment Pharmacol Ther. 2023; 58(5):537-545.

PMID: 37394976 PMC: 10720393. DOI: 10.1111/apt.17631.


Editorial: clinical outcomes in lean NAFLD - the devil is in the details. Authors' reply.

Wijarnpreecha K, Lok A, Chen V Aliment Pharmacol Ther. 2023; 57(9):1042-1043.

PMID: 37053482 PMC: 10707450. DOI: 10.1111/apt.17453.


References
1.
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

2.
Wong R, Aguilar M, Cheung R, Perumpail R, Harrison S, Younossi Z . Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2014; 148(3):547-55. DOI: 10.1053/j.gastro.2014.11.039. View

3.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal A . Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017; 67(1):123-133. PMC: 5767767. DOI: 10.1002/hep.29466. View

4.
Younossi Z, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y . The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016; 64(5):1577-1586. DOI: 10.1002/hep.28785. View

5.
Corey K, Klebanoff M, Tramontano A, Chung R, Hur C . Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci. 2016; 61(7):2108-17. PMC: 4920690. DOI: 10.1007/s10620-016-4044-2. View